| Summary: | Objective To examine interactions between Neuropsychiatric symptoms (NPS) with Pittsburgh Compound B (PiB) and fluorodeoxyglucose positron emission tomography (FDG‐PET) in predicting cognitive trajectories. Methods We conducted a longitudinal study in the setting of the population‐based Mayo Clinic Study of Aging in Olmsted County, MN, involving 1581 cognitively unimpaired (CU) persons aged ≥50 years (median age 71.83 years, 54.0% males, 27.5% APOE ɛ4 carriers). NPS at baseline were assessed using the Neuropsychiatric Inventory Questionnaire (NPI‐Q). Brain glucose hypometabolism was defined as a SUVR ≤ 1.47 (measured by FDG‐PET) in regions typically affected in Alzheimer's disease. Abnormal cortical amyloid deposition was measured using PiB‐PET (SUVR ≥ 1.48). Neuropsychological testing was done approximately every 15 months, and we calculated global and domain‐specific (memory, language, attention, and visuospatial skills) cognitive z‐scores. We ran linear mixed‐effect models to examine the associations and interactions between NPS at baseline and z‐scored PiB‐ and FDG‐PET SUVRs in predicting cognitive z‐scores adjusted for age, sex, education, and previous cognitive testing. Results Individuals at the average PiB and without NPS at baseline declined over time on cognitive z‐scores. Those with increased PiB at baseline declined faster (two‐way interaction), and those with increased PiB and NPS declined even faster (three‐way interaction). We observed interactions between time, increased PiB and anxiety or irritability indicating accelerated decline on global z‐scores, and between time, increased PiB and several NPS (e.g., agitation) showing faster domain‐specific decline, especially on the attention domain. Conclusions NPS and increased brain amyloid deposition synergistically interact in accelerating global and domain‐specific cognitive decline among CU persons at baseline.
|
|---|